Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia

Blood

Volumn 123, Issue 24, 2014, Pages 3739-3749

  Beldjord, Kheira ^a   Chevret, Sylvie ^a   Asnafi, Vahid ^b   Huguet, Françoise ^c   Boulland, Marie Laure ^d   Leguay, Thibaut ^e   Thomas, Xavier ^f   Cayuela, Jean Michel ^a   Grardel, Nathalie ^g   Chalandon, Yves ^h   Boissel, Nicolas ^a   Schaefer, Beat ⁱ   Delabesse, Eric ^c   Cavé, Hélène ^j   Chevallier, Patrice ^k   Buzyn, Agnes̀ ^b   Fest, Thierry ^d   Reman, Oumedaly ^l   Vernant, Jean Paul ^m   Lhéritier, Veŕonique ^f   Béńe, Marie C ^k   Lafage, Marina ⁿ   Macintyre, Elizabeth ^b   Ifrah, Norbert ^o   Dombret, Hervé ^a   more..

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c CHU PURPAN   (France)

^d RENNES UNIVERSITY HOSPITAL   (France)

^e HAUT LÉVÊQUE HOSPITAL   (France)

^f CENTRE HOSPITALIER LYON SUD   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h GENEVA UNIVERSITY HOSPITALS   (Switzerland)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^j HÔPITAL ROBERT DEBRÉ   (France)

^k NANTES UNIVERSITY HOSPITAL   (France)

^l CAEN UNIVERSITY HOSPITAL   (France)

^m PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁿ AIX MARSEILLE UNIVERSITY   (France)

^o ANGERS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; NOTCH1 RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER REGRESSION; FEMALE; GENE DELETION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; ONCOGENE; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PRE B LYMPHOCYTE; PRIORITY JOURNAL; RELAPSE; REMISSION; RISK FACTOR; T LYMPHOCYTE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84902685650     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-01-547695     Document Type: Article

References (44)

1. Boissel N, Auclerc MF, Lhéritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21(5):774-780. (Pubitemid 46606434)
2. de Bont JM, Holt B, Dekker AW, van der Doesvan den Berg A, Sonneveld P, Pieters R. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia. 2004;18(12):2032-2035. (Pubitemid 40028431)
3. Hallböök H, Gustafsson G, Smedmyr B, Söderhäll S, Heyman M; Swedish Adult Acute Lymphocytic Leukemia Group; Swedish Childhood Leukemia Group. Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer. 2006;107(7):1551-1561. (Pubitemid 44546916)
4. Ramanujachar R, Richards S, Hann I, et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer. 2007;48(3):254-261. (Pubitemid 46238513)
5. Stock W, La M, Sanford B, et al Children's Cancer Group; Cancer and Leukemia Group B studies. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008;112(5):1646-1654.
6. Ribera JM, Oriol A, Sanz MA, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96. J Clin Oncol. 2008;26(11):1843-1849.
7. Haïat S, Marjanovic Z, Lapusan S, et al. Outcome of 40 adults aged from 18 to 55 years with acute lymphoblastic leukemia treated with double-delayed intensification pediatric protocol. Leuk Res. 2011;35(1):66-72.
8. Rijneveld AW, van der Holt B, Daenen SM, et al; Dutch-Belgian HOVON Cooperative group. Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40. Leukemia. 2011;25(11):1697-1703.
9. Gökbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program). 2006;133-141.
10. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29(5):532-543.
11. Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27(6):911-918.
12. Brüggemann M, Gökbuget N, Kneba M. Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle. Semin Oncol. 2012;39(1):47-57.
13. Mullighan CG. The molecular genetic makeup of acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program). 2012;2012:389-396.
14. Mullighan CG, Su X, Zhang J, et al Children's Oncology Group. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5):470-480.
15. Iacobucci I, Storlazzi CT, Cilloni D, et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood. 2009;114(10):2159-2167.
16. Kuiper RP, Waanders E, van der Velden VH, et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia. 2010;24(7):1258-1264.
17. Iacobucci I, Iraci N, Messina M, et al. IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. PLoS ONE. 2012;7(7):e40934.
18. Martinelli G, Iacobucci I, Storlazzi CT, et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol. 2009;27(31):5202-5207.
19. Dörge P, Meissner B, Zimmermann M, et al. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica. 2013;98(3):428-432.
20. Ben Abdelali R, Asnafi V, Leguay T, et al Group for Research on Adult Acute Lymphoblastic Leukemia. Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study. Blood. 2011;118(19):5099-5107.
21. Jenkinson S, Koo K, Mansour MR, et al. Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial. Leukemia. 2013;27(1):41-47.
22. Trinquand A, Tanguy-Schmidt A, Ben Abdelali R, et al. Towards a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult TALL: a GRAALL study. J Clin Oncol. 2013;31(34):4333-4342.
23. Moorman AV, Harrison CJ, Buck GAN, et al Adult Leukaemia Working Party, Medical Research Council/National Cancer Research Institute. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109(8):3189-3197. (Pubitemid 46572503)
24. van der Velden VH, Cazzaniga G, Schrauder A, et al; European Study Group on MRD detection in ALL (ESG-MRD-ALL). Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21(4):604-611. (Pubitemid 46444541)
25. van Dongen JJ, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17(12):2257-2317. (Pubitemid 38072572)
26. Caye A, Beldjord K, Mass-Malo K, et al. Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2013;98(4):597-601.
27. Bergeron J, Clappier E, Radford I, et al. Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-ALLs. Blood. 2007;110(7):2324- 2330. (Pubitemid 47523151)
28. Cox D. Regression models and life tables. J R Stat Soc Series B Stat Methodol. 1972;34(2):187-220.
29. Kutner MH, Nachtsheim CJ, Neter J. Applied Linear Regression Models, 4th ed. McGraw-Hill/Irwin; 2004.
30. Kaplan EL, Meier P. Non-parametric estimations from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
31. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc Ser A Stat Soc. 1972;135:185-206.
32. Vidriales MB, Pérez JJ, López-Berges MC, et al. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood. 2003;101(12):4695-4700. (Pubitemid 36857722)
33. Brüggemann M, Raff T, Flohr T, et al German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107(3):1116-1123. (Pubitemid 43156313)
34. Holowiecki J, Krawczyk-Kulis M, Giebel S, et al. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Br J Haematol. 2008;142(2):227-237. (Pubitemid 351994055)
35. Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113(18):4153- 4162.
36. Patel B, Rai L, Buck G, et al. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. Br J Haematol. 2010;148(1):80-89.
37. Gökbuget N, Kneba M, Raff T, et al German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120(9):1868-1876.
38. Brüggemann M, Raff T, Kneba M. Has MRD monitoring superseded other prognostic factors in adult ALL? Blood. 2012;120(23):4470-4481.
39. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10(2):125-134.
40. van der Veer A, Waanders E, Pieters R, et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood. 2013;122(15):2622- 2629.
41. Moorman AV, Schwab C, Ensor HM, et al. IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. J Clin Oncol. 2012;30(25):3100-3108.
42. Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science. 2008;322(5906):1377- 1380. (Pubitemid 352775249)
43. Clappier E, Gerby B, Sigaux F, et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med. 2011;208(4):653-661.
44. Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306-313.